This article is one in a series seeking to give a face to some of the folks at RA Capital Management toiling away tirelessly and passionately to bring the next generation of medicines to patients. 

RA Capital is incredibly proud to have a number of women in senior positions and a deep bench of female biotech and investment leaders. In this piece, Sarah Reed, RA Capital’s general counsel, spoke with just three of the many phenomenal women here who have been involved in some of our recent high-profile exits.

When Capstan Therapeutics agreed to be acquired by AbbVie for a record-breaking price of $2.1B upfront, it had just started its Phase 1 study in healthy volunteers, was well-capitalized, and was on a mission to put a range of autoimmune diseases into deep remission and maybe even cure them. Some people will wonder about the significance of this deal and what lessons it may have for their own ventures. We can share our insights. We’ve been on the Capstan journey since the beginning and are incredibly proud of the team and its work. This is a story worth hearing.